Longeveron Inc.
LGVN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LGVN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LGVN
Longeveron Inc. (LGVN) is a clinical-stage biotechnology company developing laromestrocel, an investigational cell therapy, for aging-related and life-threatening conditions, with a lead Phase 2 readout expected in late 2026.
Key risk: Going concern and capital needs
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial · 1 catalyst for Longeveron Inc..
Longeveron Inc. (LGVN) is a clinical-stage biotechnology company developing laromestrocel, an investigational cell therapy, for aging-related and life-threatening conditions, with a lead Phase 2 readout expected in late 2026.
- Lead product candidate is laromestrocel, being investigated for multiple disease states and indications [sec_mda · as of 2026-08-12].
- Cash and equivalents of $10.1M as of 2026-06-30 [sec].
- Total revenue of $0.3M and net loss of -$6.1M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of $5.7M as of 2026-06-30 [sec].
- Company has raised approximately $136.0 million in gross proceeds since inception through equity financings, grants, and other sources [sec_mda · as of 2026-08-12].
What works
- Laromestrocel is being advanced for several disease states, diversifying potential clinical applications [sec_mda · as of 2026-08-12].
- The company has historically funded a large portion of its clinical programs with grant funding, reducing reliance on dilutive capital [sec_mda · as of 2026-08-12].
- A Phase 2 topline readout for laromestrocel is expected by year-end 2026, providing a key data catalyst [upcoming catalysts].
What to weigh
- The company has a going concern risk and needs to raise additional capital to fund operations [sec · filed 2026-04-10].
- Operating expenses are expected to increase substantially in the near term to support clinical and manufacturing readiness [sec_mda · as of 2025-08-13].
- Net loss of -$6.1M on minimal revenue of $0.3M for the six months ended 2026-06-30 indicates ongoing cash burn [sec].
- There is no assurance that the company will be able to secure additional financing or non-dilutive funding [sec_mda · as of 2025-08-13].
From the filings
Quoted directly from source documents.
Laromestrocel is being developed for multiple indications
“advance the clinical development of laromestrocel for the treatment of several disease states and indications”
SEC MD&A · August 12, 2026
Company has raised approximately $136.0 million in gross proceeds since inception
“Since we were formed, we have raised approximately $136.0 million in gross”
SEC MD&A · August 12, 2026
Company has a going concern risk and needs additional capital
“our financial performance and ability to continue as a going concern; the accuracy of estimates regarding the period for which our existing cash and cash equivalents will be sufficient to fund our future operating expenses”
SEC filings · April 10, 2026
Operating expenses are expected to increase to support BLA readiness
“our operating expenses and capital expenditure requirements are expected to increase throughout the remainder of calendar 2025 and in 2026 in large part to address CMC and manufacturing readiness”
SEC MD&A · August 13, 2025
Catalyst timeline
- 2026-12-31 · Phase2_Topline · laromestrocel — Phase 2 Readout: laromestrocel — Topline results from the Phase 2 trial of laromestrocel are expected, which will inform the clinical profile and potential path forward for the candidate.
Risks & what to watch (4)›
Key risks
- Going concern and capital needs — Company may need to raise additional capital to continue operations; no assurance of financing availability [sec · filed 2026-04-10].
- Clinical and regulatory uncertainty — Laromestrocel is still in clinical development; no guarantee of successful completion or regulatory approval [sec_mda · as of 2026-08-12].
- Substantial operating losses — Net loss of -$6.1M on minimal revenue of $0.3M for six months ended 2026-06-30; ongoing cash burn [sec].
- Dilution risk from future financings — Future equity or debt financings may be dilutive to existing shareholders [sec · filed 2025-08-11].
What to watch
- Phase 2 topline data for laromestrocel expected by end of 2026 [upcoming catalysts].
- Ability to secure additional financing or non-dilutive funding to support operations [sec_mda · as of 2025-08-13].
- Progress in CMC and manufacturing readiness activities for BLA [sec_mda · as of 2025-08-13].
- Cash runway and burn rate updates in future financial filings [sec · filed 2026-04-10].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Longeveron Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Longeveron Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
5.5 months
D/E 0.49 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~123d
No insider transactions in the last 180 days
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
30
Total value held
$2.7M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,084,064 | $1.1M |
| millennium management llc | 446,725 | $465K |
| blackrock, inc. | 224,198 | $233K |
| geode capital management, llc | 203,618 | $212K |
| adar1 capital management, llc | 200,000 | $208K |
| jane street group, llc | 185,656 | $193K |
| state street corp | 45,380 | $47K |
| vanguard fiduciary trust co | 38,715 | $40K |
| capital investment advisory services, llc | 26,525 | $28K |
| commonwealth equity services, llc | 25,155 | $26K |
Showing top 10 of 30 institutional holders of Longeveron Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 9.7%
- Days to cover
- 3.4
- Shares short
- 2,609,328
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LGVN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Longeveron Inc.?
Longeveron Inc. (LGVN) is a clinical-stage biotechnology company developing laromestrocel, an investigational cell therapy, for aging-related and life-threatening conditions, with a lead Phase 2 readout expected in late 2026.
What is Longeveron Inc.'s next catalyst?
Longeveron Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: laromestrocel" — expected December 31, 2026.
Who is the CEO of Longeveron Inc.?
Mr. Stephen H. Willard Esq. is the chief executive officer of Longeveron Inc. (LGVN).
Where is Longeveron Inc. headquartered?
Longeveron Inc. (LGVN) is headquartered in Miami, FL, United States.
What therapeutic areas does Longeveron Inc. focus on?
Longeveron Inc. develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.